To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch.

1. ADRs which are unexpected from the precautions for use
2. Understanding of incidence of ADRs during use of Forxiga in the real world setting
3. Factors possibly having an impact on the safety

Inclusion Criteria:

• Patients aged more than 15 years
• Patients who have been prescribed Forxiga for the first time

Exclusion Criteria:

• Patients with a history of hypersensitivity to any ingredients of this drug.
• Patients with severe ketosis, diabetic coma or precoma
• Patients with severe infections, before or after a surgery, or with serious trauma

Patients with chronic heart failure who use Forxiga for the first time.

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.